Convalescent Plasma for COVID-19 Patients (CPCP)

NCT04521036 PHASE1 COMPLETED

Prior findings in various viral respiratory diseases including SARS-CoV-related pneumonia suggest that convalescent plasma can reduce mortality, although formal proof of efficacy is still lacking. The investigators propose to evaluate intravenous administration of convalescent plasma (CP) obtained from COVID19 survivors in COVID19 patients who are in the medium stage. Supportive data exist for use of convalescent plasma in the treatment of COVID19 and other overwhelming viral illnesses. The study team wants to test the hypothesis that treatment with COVID19 CP will demonstrate salutary effects on COVID19 disease severity/duration, with the primary objective to reduce mortality. In addition, a major secondary objective to reduce the requirement for and/or duration of mechanical ventilation. This phase is to test the safety and efficacy of CP therapy.

Details

Lead sponsor	Vinmec Research Institute of Stem Cell and Gene Technology
Phase	PHASE1
Status	COMPLETED
Enrolment	4
Start date	Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jul 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• COVID 19

Interventions

• Convalescent Plasma as Therapy for Covid-19 patients

Countries

Vietnam